Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
21 studies found for:    Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Conditions: Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Arteriosclerosis;   Arterial Occlusive Diseases;   Vascular Diseases
Intervention: Procedure: CorPath-assisted Percutaneous Coronary Intervention
2 Recruiting A Complex Contraception Registry
Conditions: Diabetes;   Cardiovascular Disease;   Epilepsy;   Migraine;   Neurological Disorders;   Cancer;   Bariatric Surgery Candidate;   Organ or Tissue Transplant; Complications;   Lupus Erythematosus, Systemic;   Other Hematologic Conditions;   Other Venous Embolism and Thrombosis
Intervention:
3 Recruiting Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Condition: Abdominal Aortic Aneurysm (AAA)
Intervention: Device: Nellix System
4 Recruiting VLU Non-inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-layer Bandaging
Condition: Venous Leg Ulcer
Interventions: Device: Dual Action Pneumatic Compression Device;   Device: Multi-Layer Bandaging
5 Recruiting Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Conditions: Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
6 Recruiting Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Condition: Hereditary Angioedema
Interventions: Drug: DX-2930;   Drug: Placebo
7 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Conditions: Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom Macroglobulinemia
Intervention: Drug: ADCT-402
8 Available Expanded Access Treatment Protocol CA204-143
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab in combinination with Lenalidomide and Dexamethasone
9 Recruiting PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
Condition: Portopulmonary Hypertension
Interventions: Drug: Macitentan;   Other: Placebo
10 Recruiting Post Market Surveillance Study of the Wingspan Stent System
Condition: Intracranial Atherosclerosis
Intervention: Device: Wingspan Stent System
11 Recruiting U.S. CTEPH Registry
Conditions: Chronic Thromboembolic Pulmonary Hypertension (CTEPH);   Pulmonary Hypertension
Intervention:
12 Recruiting A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ubenimex;   Other: placebo
13 Recruiting The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Macitentan;   Drug: Tadalafil;   Drug: Selexipag
14 Recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
15 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
16 Recruiting Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Conditions: Stroke, Acute;   Cerebral Infarction
Interventions: Procedure: Endovascular Thrombectomy;   Device: Trevo Retriever;   Device: Solitaire™ FR Revascularization Device;   Device: Penumbra thrombectomy system;   Device: Covidien MindFrame Capture Revascularization Device
17 Recruiting Evaluation of the Duration of Therapy for Thrombosis in Children
Condition: Venous Thrombosis
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
18 Recruiting Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension
Conditions: Glaucoma, Open-Angle;   Ocular Hypertension
Interventions: Drug: Bimatoprost sustained-release;   Other: Sham;   Drug: Timolol;   Drug: Timolol Vehicle (placebo)
19 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
20 Recruiting sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Condition: Skin Kaposi Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Behavioral: Quality-of-Life Assessment;   Biological: Recombinant EphB4-HSA Fusion Protein

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Indicates status has not been verified in more than two years